Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Contineum Therapeutics (CTNM) Amortization of Deferred Charges (2023)

Contineum Therapeutics' Amortization of Deferred Charges history spans 1 years, with the latest figure at -$1000.0 for Q4 2023.

Quarterly Amortization of Deferred Charges changed N/A to -$1000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$1000.0 through Sep 2024, changed N/A year-over-year, with the annual reading at -$198000.0 for FY2023, N/A changed from the prior year.
Amortization of Deferred Charges came in at -$1000.0 for Q4 2023, up from -$223000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $26000.0 in Q1 2023 to a low of -$223000.0 in Q2 2023.